|Cat. No.||Species||Product Description||Structure||Purity||Feature|
|PSA-M82Ea||Mouse||Biotinylated Mouse PSCA Protein, His,Avitag™, low endotoxin (MALS verified)|
|PSA-M82E3||Mouse||Biotinylated Mouse PSCA Protein, His,Avitag™ (MALS verified)||
|PSA-H82E3||Human||Biotinylated Human PSCA Protein, His,Avitag™ (MALS verified)||
|PSA-H52H6||Human||Human PSCA Protein, His Tag||
2e5 of anti-PSCA CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human PSCA, His,Avitag (Cat. No. PSA-H82E3) and negative control protein respectively, washed and then followed by PE-SA antibody and analyzed with FACS (Routinely tested).
The purity of Biotinylated Mouse PSCA, His,Avitag (Cat. No. PSA-M82Ea) is more than 95% and the molecular weight of this protein is around 18-26 kDa verified by SEC-MALS.
The purity of Biotinylated Mouse PSCA, His,Avitag (Cat. No. PSA-M82E3) is more than 85% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
|Name||Research Code||Research Phase||Company||Indications||Clinical Trials|
|124-iodine-labeled PSCA targeting minibody (ImaginAb)||Phase 1 Clinical||University Of California At Los Angeles||Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms||Details|
|BPX-601||BPX-601||Phase 2 Clinical||Bellicum Pharmaceuticals Inc||Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms||Details|
|GEM3-PSCA||GEM3-PSCA||Phase 1 Clinical||Gemoab Monoconals, Gcp Service International||Kidney Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung||Details|
This web search service is supported by Google Inc.